Clinical Trial Update: Managed Access Programs for INC280, Capmatinib

View source ↗

Summary

The document reports that the managed access program for capmatinib (INC280) is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Capmatinib (capmatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer | Status: NO_LONGER_AVAILABLE